对乙酰氨基酚

常用名 对乙酰氨基酚 英文名 4-Acetamidophenol
CAS号 103-90-2 分子量 151.163
密度 1.3±0.1 g/cm3 沸点 387.8±25.0 °C at 760 mmHg
分子式 C8H9NO2 熔点 168-172 °C(lit.)
MSDS对乙酰氨基酚的MSDS|SDS|pdf下载 中文版 美版 闪点 188.4±23.2 °C
符号 GHS07
GHS07
信号词 Warning

 对乙酰氨基酚用途


1.药物中间体。制造偶氮染料。照相化学药品。


 对乙酰氨基酚物理化学性质

[ 密度 ]: 1.3±0.1 g/cm3
[ 沸点 ]: 387.8±25.0 °C at 760 mmHg
[ 熔点 ]: 168-172 °C(lit.)
[ 分子式 ]: C8H9NO2
[ 分子量 ]: 151.163
[ 闪点 ]: 188.4±23.2 °C
[ 精确质量 ]: 151.063324
[ PSA ]: 49.33000
[ LogP ]: 0.34
[ 蒸汽压 ]: 0.0±0.9 mmHg at 25°C
[ 折射率 ]: 1.619
[ 储存条件 ]: 1.储存于阴凉、通风的库房。远离火种、热源。保持容器密封。应与氧化剂分开存放,切忌混储。配备相应品种和数量的消防器材。储区应备有合适的材料收容泄漏物。
[ 稳定性 ]:

1.避免与氧化物接触。

2.有毒,具有刺激性,使用时应避免与眼睛及皮肤接触。

[ 水溶解性 ]: 14 g/L (20 ºC)
[ 分子结构 ]:

1、 摩尔折射率:42.40

2、 摩尔体积(cm3/mol):120.9

3、 等张比容(90.2K):326.0

4、 表面张力(dyne/cm):52.8

5、 介电常数:

6、 偶极距(10-24cm3):

7、 极化率:16.81

[ 计算化学 ]:

1.疏水参数计算参考值(XlogP):无

2.氢键供体数量:2

3.氢键受体数量:2

4.可旋转化学键数量:1

5.互变异构体数量:6

6.拓扑分子极性表面积49.3

7.重原子数量:11

8.表面电荷:0

9.复杂度:139

10.同位素原子数量:0

11.确定原子立构中心数量:0

12.不确定原子立构中心数量:0

13.确定化学键立构中心数量:0

14.不确定化学键立构中心数量:0

15.共价键单元数量:1

[ 更多 ]:

1. 性状:无色单斜方棱形式结晶。无臭。味苦。

2. 密度(g/mL,25/4℃): 1.293

3. 相对蒸汽密度(g/mL,空气=1):未确定

4. 熔点(ºC):169-170

5. 沸点(ºC,常压):未确定

6. 沸点(ºC,5.2kPa):未确定

7. 折射率:未确定

8. 闪点(ºC):未确定

9. 比旋光度(º):未确定

10. 自燃点或引燃温度(ºC):未确定

11. 蒸气压(kPa,25ºC):未确定

12. 饱和蒸气压(kPa,60ºC):未确定

13. 燃烧热(KJ/mol):未确定

14. 临界温度(ºC):未确定

15. 临界压力(KPa):未确定

16. 油水(辛醇/水)分配系数的对数值:未确定

17. 爆炸上限(%,V/V):未确定

18. 爆炸下限(%,V/V):未确定

19.溶解性:溶于甲醇、乙醇、二氯乙烯、丙酮和乙酸乙酯,微溶于乙醚和热水,几乎不溶于冷水,不溶于石油醚、戊烷和苯。

 对乙酰氨基酚MSDS

4'-羟基乙酰苯胺 修改号码:6

模块1. 化学品
产品名称: 4'-Hydroxyacetanilide
修改号码: 6

模块2. 危险性概述
GHS分类
 物理性危害未分类
 健康危害
急性毒性(经口) 第4级
生殖细胞敏感性 第2级
特异性靶器官毒性 肝脏, 消化道, 心脏, 肾脏, 中枢神经系统
- 单一接触 [第1级]
特异性靶器官毒性 呼吸系统, 睾丸
- 单一接触 [第2级]
特异性靶器官毒性 肝脏, 血液(系统), 肾脏
- 单一接触 [第1级]
特异性靶器官毒性甲状腺
- 单一接触 [第2级]
 环境危害
急性水生毒性 第2级
慢性水生毒性 第2级
GHS标签元素
 图标或危害标志
 信号词危险
 危险描述吞咽有害。
怀疑会造成遗传缺陷
对器官引起损害: 肝脏 消化道 心脏 肾脏 中枢神经系统
可能对器官产生损害: 呼吸系统 睾丸
可能因延长或接触对器官产生损害: 肝脏 血液(系统) 肾

可能因延长或接触对器官产生损害: 甲状腺
4'-羟基乙酰苯胺 修改号码:6

模块2. 危险性概述
对水生生物有毒性
长期影响对水生生物有毒性
 防范说明
[预防]使用前获取特定手册。
处理前必须阅读并理解所有安全措施。
切勿吸入。
避免释放到环境中。
使用本产品时切勿吃东西,喝水或吸烟。
处理后要彻底清洗双手。
使用个人所需的防护用具。
[急救措施] 食入:若感不适,呼叫解毒中心/医生。漱口。
如接触到或相关接触:求医/就诊。
收集溢出物。
[储存]存放处须加锁。
[废弃处置] 根据当地政府规定把物品/容器交与工业废弃处理机构。

模块3. 成分/组成信息
单一物质/混和物单一物质
化学名(中文名): 4'-羟基乙酰苯胺
百分比: >98.0%(HPLC)(N)
CAS编码: 103-90-2
俗名: 4-Acetamidophenol , Acetaminophen , Paracetamol
分子式: C8H9NO2

模块4. 急救措施
吸入: 将受害者移到新鲜空气处,保持呼吸通畅,休息。求医/就诊。
皮肤接触: 立即去除/脱掉所有被污染的衣物。用大量肥皂和水轻轻洗。
求医/就诊。
眼睛接触:用水小心清洗几分钟。如果方便,易操作,摘除隐形眼镜。
求医/就诊。
食入: 求医/就诊。漱口。
危害迹象: 腹痛, 腹泻, 嗜睡, 恶心, 意识丧失, 呕吐
紧急救助者的防护:救援者需要穿戴个人防护用品,比如橡胶手套和气密性护目镜。
医生注意事项:建议医学观察。

模块5. 消防措施
合适的灭火剂:干粉,泡沫,雾状水,二氧化碳
特殊危险性:小心,燃烧或高温下可能分解产生毒烟。
特定方法:从上风处灭火,根据周围环境选择合适的灭火方法。
非相关人员应该撤离至安全地方。
周围一旦着火:如果安全,移去可移动容器。
消防员的特殊防护用具:灭火时,一定要穿戴个人防护用品。

模块6. 泄漏应急处理
个人防护措施,防护用具, 使用特殊的个人防护用品(针对有毒颗粒的P3过滤式空气呼吸器)。远离溢出物/泄露
紧急措施:处并处在上风处。
泄露区应该用安全带等圈起来,控制非相关人员进入。
环保措施:小心,切勿排入河流等。因为考虑对环境有负面影响。
4'-羟基乙酰苯胺 修改号码:6

模块6. 泄漏应急处理
控制和清洗的方法和材料:清扫收集粉尘,封入密闭容器。注意切勿分散。附着物或收集物应该立即根据合适的
法律法规处置。

模块7. 操作处置与储存
处理
技术措施:在通风良好处进行处理。穿戴合适的防护用具。防止粉尘扩散。处理后彻底清洗双手
和脸。
注意事项:如果可能,使用封闭系统。如果粉尘或浮质产生,使用局部排气。
操作处置注意事项:避免所有部位的接触!
贮存
储存条件:保持容器密闭。存放于凉爽、阴暗处。
存放处须加锁。
远离不相容的材料比如氧化剂存放。
包装材料:依据法律。

模块8. 接触控制和个体防护
工程控制:尽可能安装封闭体系或局部排风系统。同时安装淋浴器和洗眼器。
个人防护用品
 呼吸系统防护: 防尘面具,自携式呼吸器(SCBA),供气呼吸器等。使用通过政府标准的呼吸器。依
据当地和政府法规。
 手部防护:防渗手套。
 眼睛防护:护目镜。如果情况需要,佩戴面具。
 皮肤和身体防护:防渗防护服。如果情况需要,穿戴防护靴。

模块9. 理化特性
固体
外形(20°C):
外观: 晶体-粉末
颜色:白色类白色
气味:无味
pH: 5.5 - 6.5 (saturated soln.H2O)
熔点:
169°C
沸点/沸程无资料
闪点:无资料
爆炸特性
 爆炸下限:无资料
 爆炸上限:无资料
蒸气压: 9.3x10-4Pa/25°C
密度:无资料
溶解度:
[水] 微溶于(1.4g/100mL, 20°C)
[其他溶剂]
溶于: 丙酮, 乙醇, 二甲基甲酰胺, 乙酸乙酯
微溶于:醚
不溶于: 苯, 石油醚
log水分配系数 = 0.49

模块10. 稳定性和反应性
化学稳定性:一般情况下稳定。
危险反应的可能性:未报道特殊反应性。
4'-羟基乙酰苯胺 修改号码:6

模块10. 稳定性和反应性
须避免接触的物质氧化剂
危险的分解产物: 一氧化碳, 二氧化碳, 氮氧化物 (NOx)

模块11. 毒理学信息
急性毒性: orl-rat LD50:1944 mg/kg
scu-mus LD50:310 mg/kg
ipr-rat LD50:1205 mg/kg
orl-hmn LDLo:143 mg/kg
对皮肤腐蚀或刺激:无资料
对眼睛严重损害或刺激:无资料
生殖细胞变异原性: cyt-hmn-lym 200 mg/L
cyt-hmn-orl 42860 ug/kg
dns-rat-orl 500 mg/kg
mmo-sat 100 ug/disc (+S9)
致癌性: orl-mus TDLo:135 g/kg/77W-C
orl-rat TDLo:164 g/kg/78W-C
IARC = 3 (无法对人类的致癌性进行分类)。
NTP =无资料
生殖毒性:无资料
RTECS 号码: AE4200000

模块12. 生态学信息
生态毒性:
鱼类: 96h LC50:>100 mg/L (Oryzias latipes)
甲壳类: 48h EC50:3.5 mg/L (Daphnia magna)
藻类: 72h EC50:150 mg/L (Selenastrum capricornutum)
残留性 / 降解性:无资料
潜在生物累积 (BCF):无资料
土壤中移动性
 log水分配系数: 0.49
 土壤吸收系数 (Koc):无资料
 亨利定律无资料
constant(PaM3/mol):

模块13. 废弃处置
如果可能,回收处理。请咨询当地管理部门。建议在可燃溶剂中溶解混合,在装有后燃和洗涤装置的化学焚烧炉中
焚烧。废弃处置时请遵守国家、地区和当地的所有法规。

模块14. 运输信息
联合国分类: 第9类 杂类
UN编号: 3077
正式运输名称: 环境有害物质, 固体, 不另作详细说明
包装等级: III
海洋污染物: Y

模块15. 法规信息
《危险化学品安全管理条例》(2002年1月26日国务院发布,2011年2月16日修订): 针对危险化学品的安全使用、
生产、储存、运输、装卸等方面均作了相应的规定。
4'-羟基乙酰苯胺 修改号码:6


模块16 - 其他信息
N/A

 对乙酰氨基酚毒性和生态

对乙酰氨基酚毒理学数据:

半数致死量(大鼠,经口)338 mg/kg.

对乙酰氨基酚生态学数据:

对水是极其危害的,对鱼类有毒性,切勿让产品进入水体。

CHEMICAL IDENTIFICATION

RTECS NUMBER :
AE4200000
CHEMICAL NAME :
Acetanilide, 4'-hydroxy-
CAS REGISTRY NUMBER :
103-90-2
BEILSTEIN REFERENCE NO. :
2208089
LAST UPDATED :
199806
DATA ITEMS CITED :
92
MOLECULAR FORMULA :
C8-H9-N-O2
MOLECULAR WEIGHT :
151.18
WISWESSER LINE NOTATION :
QR DMV1

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human - child
DOSE/DURATION :
591 mg/kg/2D-I
TOXIC EFFECTS :
Liver - liver function tests impaired Kidney, Ureter, Bladder - changes in tubules (including acute renal failure, acute tubular necrosis) Blood - aplastic anemia
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human - woman
DOSE/DURATION :
4962 ug/kg
TOXIC EFFECTS :
Gastrointestinal - changes in structure or function of endocrine pancreas Liver - liver function tests impaired Blood - other changes
TYPE OF TEST :
LDLo - Lowest published lethal dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human - man
DOSE/DURATION :
714 mg/kg
TOXIC EFFECTS :
Liver - other changes
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human - infant
DOSE/DURATION :
1440 mg/kg/6D
TOXIC EFFECTS :
Behavioral - irritability Gastrointestinal - hypermotility, diarrhea Nutritional and Gross Metabolic - body temperature increase
TYPE OF TEST :
LDLo - Lowest published lethal dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human
DOSE/DURATION :
143 mg/kg
TOXIC EFFECTS :
Behavioral - general anesthetic
TYPE OF TEST :
LDLo - Lowest published lethal dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human - child
DOSE/DURATION :
360 mg/kg/2D
TOXIC EFFECTS :
Gastrointestinal - nausea or vomiting Liver - other changes Skin and Appendages - dermatitis, other (after systemic exposure)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human - child
DOSE/DURATION :
801 mg/kg
TOXIC EFFECTS :
Behavioral - general anesthetic Gastrointestinal - nausea or vomiting Liver - other changes
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human - man
DOSE/DURATION :
714 mg/kg
TOXIC EFFECTS :
Cardiac - EKG changes not diagnostic of specified effects
TYPE OF TEST :
LDLo - Lowest published lethal dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human
DOSE/DURATION :
357 mg/kg
TOXIC EFFECTS :
Behavioral - anorexia (human) Behavioral - coma Gastrointestinal - nausea or vomiting
TYPE OF TEST :
LDLo - Lowest published lethal dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human - woman
DOSE/DURATION :
260 mg/kg
TOXIC EFFECTS :
Behavioral - coma Gastrointestinal - nausea or vomiting Kidney, Ureter, Bladder - changes in tubules (including acute renal failure, acute tubular necrosis)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human - woman
DOSE/DURATION :
490 mg/kg
TOXIC EFFECTS :
Behavioral - somnolence (general depressed activity) Gastrointestinal - other changes Kidney, Ureter, Bladder - other changes
TYPE OF TEST :
LDLo - Lowest published lethal dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human - man
DOSE/DURATION :
143 mg/kg/24H-I
TOXIC EFFECTS :
Behavioral - anorexia (human) Liver - hepatitis (hepatocellular necrosis), zonal Liver - jaundice, other or unclassified
TYPE OF TEST :
LDLo - Lowest published lethal dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human - woman
DOSE/DURATION :
650 mg/kg
TOXIC EFFECTS :
Vascular - BP lowering not characterized in autonomic section Vascular - other changes Nutritional and Gross Metabolic - metabolic acidosis
TYPE OF TEST :
LDLo - Lowest published lethal dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human - child
DOSE/DURATION :
50 mg/kg
TOXIC EFFECTS :
Cardiac - other changes Lungs, Thorax, or Respiration - acute pulmonary edema Kidney, Ureter, Bladder - changes in tubules (including acute renal failure, acute tubular necrosis)
TYPE OF TEST :
LDLo - Lowest published lethal dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human - woman
DOSE/DURATION :
400 mg/kg
TOXIC EFFECTS :
Behavioral - coma Liver - liver function tests impaired Nutritional and Gross Metabolic - metabolic alkalosis
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
1944 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intraperitoneal
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
1205 mg/kg
TOXIC EFFECTS :
Behavioral - somnolence (general depressed activity) Behavioral - tremor
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
338 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intraperitoneal
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
367 mg/kg
TOXIC EFFECTS :
Behavioral - analgesia Nutritional and Gross Metabolic - body temperature decrease
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Subcutaneous
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
310 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LDLo - Lowest published lethal dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Mammal - dog
DOSE/DURATION :
2 gm/kg
TOXIC EFFECTS :
Behavioral - altered sleep time (including change in righting reflex) Blood - changes in spleen Nutritional and Gross Metabolic - body temperature decrease
TYPE OF TEST :
LDLo - Lowest published lethal dose
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Mammal - dog
DOSE/DURATION :
826 mg/kg
TOXIC EFFECTS :
Behavioral - analgesia
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - guinea pig
DOSE/DURATION :
2620 mg/kg
TOXIC EFFECTS :
Behavioral - altered sleep time (including change in righting reflex) Behavioral - somnolence (general depressed activity) Behavioral - tremor
TYPE OF TEST :
LDLo - Lowest published lethal dose
ROUTE OF EXPOSURE :
Subcutaneous
SPECIES OBSERVED :
Amphibian - frog
DOSE/DURATION :
50 mg/kg
TOXIC EFFECTS :
Behavioral - altered sleep time (including change in righting reflex) Behavioral - ataxia Lungs, Thorax, or Respiration - other changes
TYPE OF TEST :
LDLo - Lowest published lethal dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Mammal - species unspecified
DOSE/DURATION :
512 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Unreported
SPECIES OBSERVED :
Mammal - species unspecified
DOSE/DURATION :
891 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
105 gm/kg/35D-C
TOXIC EFFECTS :
Liver - other changes Nutritional and Gross Metabolic - weight loss or decreased weight gain Related to Chronic Data - death
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
68 gm/kg/13W-C
TOXIC EFFECTS :
Liver - other changes Kidney, Ureter, Bladder - changes in bladder weight Nutritional and Gross Metabolic - weight loss or decreased weight gain
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
6080 mg/kg/19D-I
TOXIC EFFECTS :
Gastrointestinal - other changes Liver - changes in liver weight Blood - changes in leukocyte (WBC) count
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intraperitoneal
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
1600 mg/kg/2D-I
TOXIC EFFECTS :
Liver - other changes Biochemical - Enzyme inhibition, induction, or change in blood or tissue levels - hepatic microsomal mixed oxidase (dealkylation, hydroxylation, etc.) Biochemical - Enzyme inhibition, induction, or change in blood or tissue levels - cytochrome oxidases (including oxidative phosphorylation)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
136 gm/kg/13W-C
TOXIC EFFECTS :
Liver - other changes Kidney, Ureter, Bladder - changes in bladder weight Nutritional and Gross Metabolic - weight loss or decreased weight gain
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
336 gm/kg/40W-C
TOXIC EFFECTS :
Liver - hepatitis (hepatocellular necrosis), diffuse Liver - other changes Liver - changes in liver weight
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
164 gm/kg/78W-C
TOXIC EFFECTS :
Tumorigenic - Carcinogenic by RTECS criteria Kidney, Ureter, Bladder - tumors
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
135 gm/kg/77W-C
TOXIC EFFECTS :
Tumorigenic - Carcinogenic by RTECS criteria Liver - hepatitis (hepatocellular necrosis), zonal Liver - tumors
TYPE OF TEST :
TD - Toxic dose (other than lowest)
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
270 gm/kg/77W-C
TOXIC EFFECTS :
Tumorigenic - equivocal tumorigenic agent by RTECS criteria Liver - tumors Endocrine - other changes
TYPE OF TEST :
TD - Toxic dose (other than lowest)
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
329 gm/kg/78W-C
TOXIC EFFECTS :
Tumorigenic - Carcinogenic by RTECS criteria Liver - tumors
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
650 mg/kg
SEX/DURATION :
female 29 week(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Newborn - Apgar score (human only) Reproductive - Effects on Newborn - other neonatal measures or effects Reproductive - Effects on Newborn - other postnatal measures or effects
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
417 mg/kg
SEX/DURATION :
female 20 week(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue) Reproductive - Specific Developmental Abnormalities - hepatobiliary system
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
1300 mg/kg
SEX/DURATION :
female 31-32 week(s) after conception
TOXIC EFFECTS :
Reproductive - Maternal Effects - other effects Reproductive - Effects on Embryo or Fetus - other effects to embryo Reproductive - Effects on Newborn - other neonatal measures or effects
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
1500 mg/kg
SEX/DURATION :
female 8-19 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
12500 mg/kg
SEX/DURATION :
female 14 day(s) pre-mating female 1-11 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - cytological changes (including somatic cell genetic material)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
1 gm/kg
SEX/DURATION :
female 3 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Newborn - growth statistics (e.g.%, reduced weight gain) Reproductive - Effects on Newborn - behavioral Reproductive - Effects on Newborn - other postnatal measures or effects
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
35 gm/kg
SEX/DURATION :
male 70 day(s) pre-mating
TOXIC EFFECTS :
Reproductive - Paternal Effects - testes, epididymis, sperm duct Reproductive - Paternal Effects - other effects on male
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
25 mg/kg
SEX/DURATION :
male 1 day(s) pre-mating
TOXIC EFFECTS :
Reproductive - Paternal Effects - spermatogenesis (incl. genetic material, sperm morphology, motility, and count)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
600 mg/kg
SEX/DURATION :
male 1 day(s) pre-mating
TOXIC EFFECTS :
Reproductive - Paternal Effects - spermatogenesis (incl. genetic material, sperm morphology, motility, and count) Reproductive - Paternal Effects - testes, epididymis, sperm duct
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
2500 mg/kg
SEX/DURATION :
female 6-15 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue) Reproductive - Specific Developmental Abnormalities - musculoskeletal system
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
2500 mg/kg
SEX/DURATION :
female 6-15 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - urogenital system
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
2 gm/kg
SEX/DURATION :
female 1 day(s) pre-mating
TOXIC EFFECTS :
Reproductive - Fertility - other measures of fertility
TYPE OF TEST :
Micronucleus test
TYPE OF TEST :
Cytogenetic analysis
TYPE OF TEST :
Sister chromatid exchange
TYPE OF TEST :
Unscheduled DNA synthesis
TYPE OF TEST :
Micronucleus test
TYPE OF TEST :
DNA damage
TYPE OF TEST :
Unscheduled DNA synthesis
TYPE OF TEST :
Cytogenetic analysis
TYPE OF TEST :
Cytogenetic analysis
TYPE OF TEST :
Sister chromatid exchange
TYPE OF TEST :
Sex chromosome loss and nondisjunction

MUTATION DATA

TYPE OF TEST :
Sister chromatid exchange
TEST SYSTEM :
Rodent - hamster Lung
DOSE/DURATION :
1 mmol/L
REFERENCE :
MUTAEX Mutagenesis. (Oxford Univ. Press, Pinkhill House, Southfield Road, Eynsham, Oxford OX8 1JJ, UK) V.1- 1986- Volume(issue)/page/year: 3,51,1988 *** REVIEWS *** IARC Cancer Review:Animal Limited Evidence IMEMDT IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man. (WHO Publications Centre USA, 49 Sheridan Ave., Albany, NY 12210) V.1- 1972- Volume(issue)/page/year: 50,307,1990 IARC Cancer Review:Human Inadequate Evidence IMEMDT IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man. (WHO Publications Centre USA, 49 Sheridan Ave., Albany, NY 12210) V.1- 1972- Volume(issue)/page/year: 50,307,1990 IARC Cancer Review:Group 3 IMEMDT IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man. (WHO Publications Centre USA, 49 Sheridan Ave., Albany, NY 12210) V.1- 1972- Volume(issue)/page/year: 50,307,1990 TOXICOLOGY REVIEW JRPMAP Journal of Reproductive Medicine. (2 Jacklynn Ct., St. Louis, MO 63132) V.3- 1969- Volume(issue)/page/year: 12,27,1974 TOXICOLOGY REVIEW AUHPAI Australian Journal of Hospital Pharmacy. (B.R. Miller, POB 125, Heidelberg, Vic., Australia) V.1- 1971- Volume(issue)/page/year: 3(3),100,1973 TOXICOLOGY REVIEW CTOXAO Clinical Toxicology. (New York, NY) V.1-18, 1968-81. For publisher information, see JTCTDW. Volume(issue)/page/year: 12,601,1978 TOXICOLOGY REVIEW NTIS** National Technical Information Service. (Springfield, VA 22161) Formerly U.S. Clearinghouse for Scientific & Technical Information. Volume(issue)/page/year: PB282-666 TOXICOLOGY REVIEW OBGNAS Obstetrics and Gynecology. (Elsevier Science Pub. Co., Inc., 52 Vanderbilt Ave., New York, NY 10017) V.1- 1953- Volume(issue)/page/year: 58,57S,1981 *** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA *** NIOSH OCCUPATIONAL EXPOSURE SURVEY DATA : NOHS - National Occupational Hazard Survey (1974) NOHS Hazard Code - 80396 No. of Facilities: 1829 (estimated) No. of Industries: 7 No. of Occupations: 14 No. of Employees: 9269 (estimated) NOES - National Occupational Exposure Survey (1983) NOES Hazard Code - 80396 No. of Facilities: 1261 (estimated) No. of Industries: 7 No. of Occupations: 26 No. of Employees: 65107 (estimated) No. of Female Employees: 56260 (estimated)

 对乙酰氨基酚安全信息

[ 符号 ]: GHS07
GHS07
[ 信号词 ]: Warning
[ 危害声明 ]: H302-H315-H317-H319
[ 警示性声明 ]: P280-P301 + P312 + P330-P305 + P351 + P338
[ 个人防护装备 ]: dust mask type N95 (US);Eyeshields;Gloves
[ 危害码 (欧洲) ]: Xn
[ 风险声明 (欧洲) ]: R22:Harmful if swallowed. R36/37/38:Irritating to eyes, respiratory system and skin . R52/53:Harmful to aquatic organisms, may cause long-term adverse effects in the aquatic environment . R36/38:Irritating to eyes and skin . R40:Limited evidence of a carci
[ 安全声明 (欧洲) ]: S26-S36-S61-S37/39
[ 危险品运输编码 ]: NONH for all modes of transport
[ WGK德国 ]: 1
[ RTECS号 ]: AE4200000
[ 海关编码 ]: 29242930

 对乙酰氨基酚制备

对氨基酚乙酰化而得。方法1:将对氨基酚加入稀乙酸中,再加入冰醋酸,升温至150℃反应7h,加入乙酐,再反应2h,检查终点,合格后冷却至25℃以下,甩滤,水洗至无乙酸味,甩干,得粗品。方法2:将对氨基酚、冰醋酸及含酸50%以上的酸母液一起蒸馏,蒸出稀酸的速度为每小时馏出总量的十分之一,待内温升至130℃以上,取样检查对氨基酚残留量低于2.5%,加入稀酸(含量50%以上),冷却结晶。甩滤,先用少量稀酸洗涤,再用大量水洗至滤液接近无色,得粗品。方法1的收率为90%,方法2的收率为90-95%。精制方法:将水加热至近沸时投入粗品。升温至全溶,加入用水浸泡过的活性炭,用稀乙酸调节至pH=4.2-4.6,沸腾10min。压滤,滤液加少量重亚硫酸钠。冷却至20℃以下,析出结晶。甩滤,水洗,干燥得原料药扑热息痛成品。其他的生产方法还有:(1)在冰醋酸中用锌还原对硝基苯酚,同时乙酰化得到对乙酰氨基酚;(2)将对羟基苯乙酮生成的腙,置于硫酸酸性溶液中,加入亚硝酸钠,转位生成对乙酰氨基酚。

 对乙酰氨基酚海关

[ 海关编码 ]: 29242930

 对乙酰氨基酚文献524

更多文献
Characterization of a highly sensitive and selective novel trapping reagent, stable isotope labeled glutathione ethyl ester, for the detection of reactive metabolites.

J. Pharmacol. Toxicol. Methods 76 , 83-95, (2015)

Glutathione (GSH) trapping assays are widely used to predict the post-marketing risk for idiosyncratic drug reactions (IDRs) in the pharmaceutical industry. Although several GSH derivatives have been ...

Application of IL-36 receptor antagonist weakens CCL20 expression and impairs recovery in the late phase of murine acetaminophen-induced liver injury.

Sci. Rep. 5 , 8521, (2015)

Overdosing of the analgesic acetaminophen (APAP, paracetamol) is a major cause of acute liver injury. Whereas toxicity is initiated by hepatocyte necrosis, course of disease is regulated by mechanisms...

Simple and reliable HPLC method for the monitoring of methotrexate in osteosarcoma patients.

J. Chromatogr. Sci. 52(7) , 590-5, (2014)

Methotrexate (MTX) is a dihydrofolate reductase inhibitor that is used for the treatment of tumors and autoimmune diseases. Several automated binding assays are used in clinical practice and numerous ...